Mononine

"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...

For Patients

Mononine (coagulation factor IX human) is a clotting factor used to treat or prevent bleeding in people with hemophilia B. This medication is not for treating people with hemophilia A factor VII deficiency. This medication is available in generic form. Common side effects include headache; warmth or tingly feeling under your skin; nausea, vomiting; dizziness; or pain, redness, or swelling where the medicine was injected.

The dose of Mononine to be infused, as well as the frequency of infusions, will vary with each patient and with the clinical situation. Mononine may interact with other drugs. Tell your doctor all medications and supplements you use. Mononine may be harmful to a fetus. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.

Our Mononine (coagulation factor IX human) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

There is a potential risk of thromboembolic episodes following the administration
of Mononine® (see WARNINGSand PRECAUTIONS).

The patient should be monitored closely during the infusion of Mononine® (coagulation factor ix (human))
to observe for the development of any reaction. If any reaction takes place
that is thought to be related to the administration of Mononine® (coagulation factor ix (human)) , the rate
of infusion should be decreased or the infusion stopped, as dictated by the
response of the patient. Should evidence of an acute hypersensitivity reaction
be observed, the infusion should be stopped promptly and appropriate countermeasures
and supportive therapy should be administered.